Facebook Twitter YouTube Google Plus

B.) State Assistance on Insurance Appeals

Joy Y. Hatchette, JD
Maryland Insurance Administration

Joy Y. Hatchette was named the Associate Commissioner for Consumer Education and Advocacy in July of 2004. This unit is responsible for providing consumers with information so that they are better able to understand their rights and obligations under their insurance policies. The Unit also attempts to facilitate the prompt resolution of automobile and homeowners claims through a pilot program. She is a graduate of the University of Virginia and received a J.D. degree from the University of Virginia Law School. She is a member of the Maryland, District of Columbia and Virginia Bars.


View the video presentation by clicking on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion